Skip to main content

Lara D. Compton





Lara is a trusted advisor to clients ranging from traditional health care providers to disrupter digital health platforms as they navigate the practical and regulatory challenges of health care innovation. Her unique depth of knowledge across HIPAA privacy and other regulatory issues governing the use of data, state and federal fraud and abuse laws, business planning and operational issues has led colleagues to describe Lara as the “Swiss Army knife” of health care problem-solving.

Working at the intersection of health care and technology, Lara counsels telemedicine and other digital health clients on business plan strategy and implementation, state-specific telemedicine regulation, corporate practice of medicine, the scope of practice, fee splitting, anti-kickback, reimbursement, and other health care regulatory issues. Leveraging her prior in-house experience at two nonprofit health systems, she also advises health care providers on the incorporation of telehealth and other technology infrastructures, which has seen a vast uptick as a result of the COVID-19 pandemic.

Lara advises health care providers, clinical trials companies, ancillary providers, technology start-ups, HMOs, insurance companies, and large technology companies on HIPAA and other health data privacy and security regulations, including developing and implementing HIPAA compliance programs. She has also led significant HIPAA breach investigations, advising clients on risk management and mitigation efforts.

Prior to joining Mintz, Lara was a partner at a boutique health care law firm, where she helped lead the regulatory practice, guiding clients not only on risk avoidance but also on essential challenges of growth, including the transition to value-based care arrangements and the development of new health technology and digital health–related products and services. She also served as an in house attorney at two nonprofit health systems, Sutter Health and Community Medical Centers, where she advised extensively on Anti-Kickback, Stark Law, day-to-day operational risk and cost control management as well as creating, evaluating and implementing internal policies, compliance programs, and marketing and training initiatives.

Lara is regularly invited to speak on challenges facing the health care industry, including HIPAA and other regulatory issues. Lara will discuss data privacy and security, fraud and abuse, HIPAA concerns, interoperability, and licensing issues on an upcoming webinar titled Digital Health in the Metaverse.

She maintains an active pro bono practice and has been recognized as a Pro Bono Champion by the American Health Lawyers Association.

A member of the LA Tri Club, Lara trains as a triathlete, runs several triathlons a year, and competes in the 70.3-mile Half Ironman.


  • University of the Pacific (JD, with distinction)
  • University of the Pacific (BA, cum laude)


Telehealth, Digital Health, and Health Information Technology

  • Structured health technology business models to comply with health care laws and regulations.
  • Represented several telehealth and management company clients in responding to California Medical Board information requests and investigations.
  • Managed regulatory due diligence in connection with the proposed sale of a telehealth provider.
  • Successfully negotiated a software development agreement with a large health care system for a software start-up client.
  • Performed regulatory due diligence for a large health care distribution company’s purchase of a health care technology company.
  • Provided ongoing health care regulatory advice to an EHR company.

Hospitals, Health Systems, and Other Health Care Providers

  • Represented California hospitals in evaluating, negotiating, and drafting physician agreements, including professional services agreements, administrative services agreements, call coverage, and hospital-based agreements.
  • Successfully defended a hospital in a million-dollar dispute with the State of California over an incentive it had earned for being an early adopter of electronic health records (EHR). After a routine audit, the State alleged that our client had counted patients wrongly and should only have received $3.27 million of the $4.21 million it had been paid. The discrepancy turned on complex definitions about what constituted a patient day. Specifically, the State alleged that psychiatric bed days were not eligible to be counted in the total bed days for EHR purposes. We argued that the billing and cost reporting of the psychiatric bed days for our client were countable under the State’s program. The administrative law judge agreed with our position and cut the refund request down to approximately $192,000.
  • Developed business associate toolkit to assist a hospital client in managing business associate relationships.
  • Structured joint patient assistance program to address health information privacy and security requirements.
  • Developed a toolkit to assist a hospital client in managing patients who are refusing discharge or are otherwise difficult to place in an appropriate level of care.
  • Restructured management services agreements to comply with California corporate practice of medicine prohibitions.
  • Investigated health care compliance implementation deficiencies for a hospital system and provided recommendations for improving the compliance program.
  • Served as lead regulatory counsel to a large health system in its Chapter 11 bankruptcy case, the largest hospital bankruptcy in US history. The matter has involved corporate and regulatory support for the system’s day-to-day operations as well as extensive regulatory work on the sale of the system’s six hospitals, including counsel regarding California attorney general conditions and the approval process.
  • Managed due diligence and pre- and post-acquisition notices for venture capital purchase of multiple ambulatory surgery centers and pain clinics.

Life Sciences and Medical Devices

  • Negotiated settlement of disciplinary action with the California Board of Pharmacy for a medical device wholesaler.
  • Evaluated medical device and biotechnology company marketing campaigns for compliance with the federal Anti-Kickback Statute and other fraud and abuse laws.
  • Evaluated proposed marketing materials for stem cell products.
  • Developed a 50-state, post-acquisition regulatory filing plan for a large diagnostics company.

Recognition & Awards

  • Los Angeles Business Journal: Leaders in Law - Firm Attorney Nominees (2021)
  • Recognized by the Los Angeles Business Journal as one of the Trusted Advisors of the Year for the Health Care Leadership and Panel Awards - Attorney Nominees (2021)
  • American Health Lawyers Association: Pro Bono Champion (2014)


  • Member, American Health Lawyers Association
  • Member, California Society for Healthcare Attorneys
  • Vice Chair, LACBA-LACMA Committee on Biomedical Ethics


Health Care Viewpoints Thumbnail

White House Issues Telehealth Guidance on Substance Use Disorder Services

July 11, 2022 | Blog | By Lara Compton, Cody Keetch, Jean D. Krebs

On June 22, 2022, the White House Office of National Drug Control Policy (ONDCP) issued guidance advocating for Congress and federal agencies to make permanent certain telehealth access measures for people struggling with substance use disorders (SUD). The guidance, titled Telehealth and Substance Use Disorder Services in the Era of Covid-19: Review and Recommendations (Guidance), made four recommendations geared at increasing telehealth access, utilization, and equity among individuals who have experienced an SUD. This blogpost with provide an analysis of the four recommendations and their implications. 
Read more
Health Care Viewpoints Thumbnail

Potential Pitfalls of Telehealth Prescribing

May 31, 2022 | Blog | By Lara Compton, Ellen Janos, Cassandra Paolillo

As we’ve previously covered, while Congress has acted to extend certain COVID-era telehealth flexibilities (mostly related to Medicare coverage) beyond the Public Health Emergency (PHE), the future of prescribing controlled substances via telehealth is uncertain.  Although the American Telemedicine Association and other industry groups continue to advocate for changes to allow telehealth providers to prescribe controlled substances in certain circumstances, without further action by Congress or the Drug Enforcement Administration (DEA), telehealth providers who prescribe controlled substances will need to conduct an in-person examination of the patient once the PHE ends. 
Read more
Webinar Reference Image

Webinar Recording: Telehealth Risk Management

April 6, 2022 | Webinar | By Nancy Adams, Lara Compton, Todd Rosenbaum, Jennifer Rubin

Read more
Pro Bono Viewpoint
Many of our nation’s 18 million veterans experience significant day-to-day challenges related to their time in the military. Through our pro bono legal counsel and the firm’s community services, including a holiday gift drive for veterans, we assist many nonprofit and advocacy organizations working to improve veterans’ lives.
Read more
Podcast Viewpoint Image
In this episode of the Health Law Diagnosed podcast, members of the Mintz Health Law team discuss their health law–focused 2022 New Year’s resolutions and how they’re helping clients and colleagues navigate the continued challenges and opportunities of the current era.
Read more
Health Care Viewpoints Thumbnail
In the weeks leading up to FDA’s October 14, 2021 Transparency of AI/ML Enabled Medical Devices Workshop (Workshop) we took a brief look at the history of FDA’s regulation of medical device software and the agency’s more recent efforts in regulating digital health. In this post, we will provide an overview of the topics discussed at the Workshop and our impressions of the agency’s likely next steps.
Read more
Health Care Viewpoints Thumbnail

California’s Senate Bill 41: The Genetic Information Privacy Act

October 19, 2021 | Blog | By Stephnie John, Lara Compton

Our previous blog post on pending California privacy legislation included a prediction that has since materialized: Governor Newsom signed the Genetic Information Privacy Act (“GIPA”) on October 6, 2021, and the law will go into effect on January 1, 2022. GIPA establishes a number of mechanisms to close the existing gap in the protection of genetic information under the current framework of federal and state privacy laws. As discussed in our earlier post, GIPA contains a robust penalty structure, but it includes a number of carve-outs and does not apply to entities already subject to regulation under other health information privacy laws. Notably, GIPA does not reduce or eliminate obligations under other laws, including California’s more broadly applicable consumer privacy laws, such as the CCPA and breach notification statute, as recently amended by AB 825. Given Governor Newsom’s former concern about GIPA’s interference with mandatory COVID-19 testing reporting, the law also does not apply to tests that are conducted exclusively to diagnose whether an individual has a specific disease.
Read more
Health Care Viewpoints Thumbnail
In our last post, we took a brief look back through history at FDA’s approach to regulating medical device software and found that there is little distinction from the agency’s approach to hardware devices. Recently, however, FDA has announced several digital health initiatives aimed at improving the agency’s resources and policies governing software and data systems (including its own internal data systems) and changing the way the agency handles pre-market reviews of and compliance activities for software as a medical device (SaMD) and SaMD manufacturers. In this post, we will review FDA’s digital health improvement highlights from the past few years and take a quick look at the agenda for the transparency of AI/ML-enabled medical devices workshop scheduled for October 14, 2021.
Read more
Health Care Viewpoints Thumbnail
October 10th was the last day for Governor Newsom to sign or veto laws that were passed by the legislature this year. 2021 was a busy year for California legislators, who put forth hundreds of health-related bills in the wake of the COVID-19 pandemic. Unsurprisingly, not all of the bills became law (although some of them may be revisited next year). This blog post provides a summary of a few of the new health care laws that were signed into law by Governor Newsom, covering a wide range of health care providers.   
Read more
Health Care Viewpoints Thumbnail
In anticipation of FDA’s virtual public workshop on transparency of artificial intelligence/machine learning (AI/ML)-enabled medical devices scheduled for October 14, 2021, we will be posting a series detailing the history behind FDA’s regulation of software and then reporting our impressions of FDA’s presentations and statements from various attending stakeholders following meeting. In this part, we briefly summarize FDA’s traditional approach to regulating software and how software development quickly revealed the limitations of the original regulatory framework established in the 1976 Medical Device Amendments to the Federal Food, Drug, and Cosmetic Act (FD&C Act).
Read more



The Evolving Health Care Privacy Landscape

Women Business Leaders of the U.S. Health Care Industry Foundation (WBL) Event

Online Event

Webinar Reference Image

Telehealth Risk Management


Online Event

Webinar Reference Image

Health Law Review 2021 Virtual Fall Symposium

Indiana University Robert H. McKinney School of Law

Online Event

Conference Reference Image

Cultivating Well-Being and Success


Shutters on the Beach, Santa Monica, CA

Seminar Reference Image

Health Care Leadership Panel & Awards

Los Angeles Business Journal

Virtual Event

Event Reference Image

Provider Compliance: Information Blocking and Patient Access

California Society for Healthcare Attorneys


Webinar Reference Image